645 related articles for article (PubMed ID: 29138992)
1. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
Medeiros da Frota Ribeiro C; Riva-Posse P
Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
[TBL] [Abstract][Full Text] [Related]
2. Ketamine: Future Treatment For Unresponsive Depression?
Frere M; Tepper J
Ir Med J; 2016 Sep; 109(8):453. PubMed ID: 28124853
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression.
McMullen EP; Lee Y; Lipsitz O; Lui LMW; Vinberg M; Ho R; Rodrigues NB; Rosenblat JD; Cao B; Gill H; Teopiz KM; Cha DS; McIntyre RS
Adv Ther; 2021 Jun; 38(6):2795-2820. PubMed ID: 33929660
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
[TBL] [Abstract][Full Text] [Related]
6. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression.
Liu W; Zhou Y; Zheng W; Wang C; Zhan Y; Lan X; Zhang B; Li H; Chen L; Ning Y
J Affect Disord; 2019 Dec; 259():1-6. PubMed ID: 31430662
[TBL] [Abstract][Full Text] [Related]
7. Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression: A Case Report.
Bartova L; Weidenauer A; Dold M; Naderi-Heiden A; Kasper S; Willeit M; Praschak-Rieder N
J ECT; 2017 Sep; 33(3):e31-e32. PubMed ID: 28520578
[No Abstract] [Full Text] [Related]
8. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
[TBL] [Abstract][Full Text] [Related]
9. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
[TBL] [Abstract][Full Text] [Related]
10. Maintenance Ketamine Therapy for Treatment-Resistant Depression.
Archer S; Chrenek C; Swainson J
J Clin Psychopharmacol; 2018 Aug; 38(4):380-384. PubMed ID: 29912788
[TBL] [Abstract][Full Text] [Related]
11. Esketamine for treatment resistant depression.
Swainson J; Thomas RK; Archer S; Chrenek C; MacKay MA; Baker G; Dursun S; Klassen LJ; Chokka P; Demas ML
Expert Rev Neurother; 2019 Oct; 19(10):899-911. PubMed ID: 31282772
[No Abstract] [Full Text] [Related]
12. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
[TBL] [Abstract][Full Text] [Related]
14. Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: A randomized control study.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
J Affect Disord; 2018 Jan; 225():709-714. PubMed ID: 28922734
[TBL] [Abstract][Full Text] [Related]
15. Frontiers in Therapy of Treatment-Resistant-Depression: A Future Role of Ketamine?
Kwak S; Tiller D; Tucker P
J Okla State Med Assoc; 2015 Mar; 108(3):88-9. PubMed ID: 26242015
[TBL] [Abstract][Full Text] [Related]
16. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety.
Szarmach J; Cubała WJ; Włodarczyk A; Wiglusz MS
Psychiatr Danub; 2019 Sep; 31(Suppl 3):585-590. PubMed ID: 31488795
[TBL] [Abstract][Full Text] [Related]
17. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
18. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
De Gioannis A; De Leo D
Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
[No Abstract] [Full Text] [Related]
19. Role of copper and ketamine in major depressive disorder - an update.
Słupski J; Słupska A; Szałach ŁP; Włodarczyk A; Górska N; Szarmach J; Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Wiglusz MS; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):520-523. PubMed ID: 31488784
[TBL] [Abstract][Full Text] [Related]
20. [Ketamine--a new treatment option for therapy-resistant depression].
Köhler S; Betzler F
Fortschr Neurol Psychiatr; 2015 Feb; 83(2):91-7. PubMed ID: 25723773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
